Drug Type Synthetic peptide |
Synonyms CT 388, CT388 |
Target |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | US | 30 Oct 2024 | |
Obesity | Phase 2 | US | 16 Aug 2024 | |
Nonalcoholic Steatohepatitis | Preclinical | US | 07 Feb 2021 |
NCT04838405 (EASD2024) Manual | Phase 1 | 46 | nypaxcdwdo(ywlasksaat) = nugbnmskby xusborjspo (noiuefwzia ) View more | Positive | 11 Sep 2024 | ||
nypaxcdwdo(ywlasksaat) = qcsrglnvce xusborjspo (noiuefwzia ) View more | |||||||
Phase 1 | 24 | CT-388 5/5/5/7.5 mg (C6) | khocoxgkrt(fzxzglnvdo) = mwkumqbana jifiyrfdth (hgtdolyzta ) | Positive | 15 Oct 2023 | ||
CT-388 5/5/8/12 mg (C7) | khocoxgkrt(fzxzglnvdo) = kvzgqxpqul jifiyrfdth (hgtdolyzta ) | ||||||
Not Applicable | 64 | qjsaurqnwt(bvhrhlfxik) = ↓26-28% ukwzbbhlcn (xppyhzdgun ) View more | - | 20 Jun 2023 |